THIO, a first-in-class agent, targets telomeres, inducing cancer cell death and activating immune responses in NSCLC. The THIO-101 trial showed a median overall survival of 16.9 months, surpassing ...

As of January 15, 2025, third line (3L) data showed median overall survival (OS) of 16.9 months for the 22 NSCLC patients who received at least one dose of THIO (the intent-to-treat population ...

The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...

In summary, MAIA Biotechnology’s recent updates regarding its Phase 2 THIO-101 trial demonstrate the company’s commitment to communicating significant developments in its oncology research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Super Retail Group Limited (SUL). However, you won't necessarily see their names in the company ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today ...

Supercheap Auto (SCA): retailing of auto parts and accessories, tools and equipment; rebel: retailing of sporting equipment and apparel; BCF: retailing of boating, camping and outdoor equipment ...